[{"orgOrder":0,"company":"Dana Solutions","sponsor":"Curi Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Human iPSC-derived cardiomyocytes","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dana Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dana Solutions \/ Curi Bio","highestDevelopmentStatusID":"2","companyTruncated":"Dana Solutions \/ Curi Bio"},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Plasma-based therapies","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Alkahest","amount2":0.14999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Alkahest \/ Grifols","highestDevelopmentStatusID":"2","companyTruncated":"Alkahest \/ Grifols"},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"A*STAR","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Peptide","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Cytochrome C oxidase","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Duke-NUS Medical School","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Duke-NUS Medical School \/ A*STAR","highestDevelopmentStatusID":"2","companyTruncated":"Duke-NUS Medical School \/ A*STAR"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$45.0 million","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"TfR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Ionis","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ Ionis"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","upfrontCash":"$6.5 million","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"siRNA Therapeutics","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"OliX Pharmaceutical","amount2":0.46000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"OliX Pharmaceutical \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Cardurion Pharmaceutical","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Cardurion Pharmaceutical \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Cardurion Pharmaceutical \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Elixirgen Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"ZSCAN4-based Therapeutic","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Taisho Pharmaceutical \/ Elixirgen Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Taisho Pharmaceutical \/ Elixirgen Therapeutics"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Flagship Pioneering \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Novo Nordisk"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Phlox Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Phlox Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Solid Biosciences \/ Phlox Therapeutics"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Abbisko Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Abbisko Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"StrideBio","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"StrideBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"StrideBio \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Bitterroot Bio \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot Bio \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Cholesgen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Cholesgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cholesgen \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Cholesgen \/ AstraZeneca"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Exosome-encapsulated AAV-based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Financing","leadProduct":"LX2021","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lexeo Therapeutics \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Institute of Cardiovascular and Metabolic Diseases","sponsor":"CSL","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"EUROPE","productType":"Undisclosed","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Institute of Cardiovascular and Metabolic Diseases","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Institute of Cardiovascular and Metabolic Diseases \/ CSL","highestDevelopmentStatusID":"2","companyTruncated":"Institute of Cardiovascular and Metabolic Diseases \/ CSL"},{"orgOrder":0,"company":"Ethris","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"ETH51","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ethris \/ Heqet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Heqet Therapeutics"},{"orgOrder":0,"company":"Buck Institute for Research on Aging","sponsor":"Hevolution Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","date":"November 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Buck Institute for Research on Aging","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Buck Institute for Research on Aging \/ Hevolution Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Buck Institute for Research on Aging \/ Hevolution Foundation"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Biotheus","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bitterroot Bio \/ Biotheus","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot Bio \/ Biotheus"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"iPSC-based Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bayer AG"},{"orgOrder":0,"company":"Multiply Labs","sponsor":"Retro Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Multiply Labs","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Multiply Labs \/ Retro Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Multiply Labs \/ Retro Biosciences"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
